Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Conditions

• Recurrent Adult Diffuse Large Cell Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Laboratory Biomarker Analysis — OTHER
  Correlative studies
• Selumetinib — DRUG
  Given PO

Study Details

This phase II clinical trial is studying how well selumetinib works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date

Dec 31, 2010

Status verified

Jul 2014

Primary completion

Feb 28, 2014

Completion

May 31, 2014

Study Design

Enrollment

16 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (selumetinib)
  Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity

Primary Outcome Measure

Response Rate (Complete Response [CR] and Partial Response [PR]) in Patients Treated With Selumetinib [ Time Frame: Up to 3 years ]

Locations (16)

Find similar trials in Chicago, IL